GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Haemonetics Corp (NYSE:HAE) » Definitions » ROE %

Haemonetics (Haemonetics) ROE %

: 13.61% (As of Dec. 2023)
View and export this data going back to 1991. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Haemonetics's annualized net income for the quarter that ended in Dec. 2023 was $125 Mil. Haemonetics's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $918 Mil. Therefore, Haemonetics's annualized ROE % for the quarter that ended in Dec. 2023 was 13.61%.

The historical rank and industry rank for Haemonetics's ROE % or its related term are showing as below:

HAE' s ROE % Range Over the Past 10 Years
Min: -7.18   Med: 5.99   Max: 14.73
Current: 14.73

During the past 13 years, Haemonetics's highest ROE % was 14.73%. The lowest was -7.18%. And the median was 5.99%.

HAE's ROE % is ranked better than
85.96% of 812 companies
in the Medical Devices & Instruments industry
Industry Median: 0.27 vs HAE: 14.73

Haemonetics ROE % Historical Data

The historical data trend for Haemonetics's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haemonetics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.75 12.20 12.05 5.86 14.72

Haemonetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.51 14.75 19.51 11.33 13.61

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Haemonetics's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haemonetics ROE % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's ROE % distribution charts can be found below:

* The bar in red indicates where Haemonetics's ROE % falls into.



Haemonetics ROE % Calculation

Haemonetics's annualized ROE % for the fiscal year that ended in Mar. 2023 is calculated as

ROE %=Net Income (A: Mar. 2023 )/( (Total Stockholders Equity (A: Mar. 2022 )+Total Stockholders Equity (A: Mar. 2023 ))/ count )
=115.401/( (749.424+817.997)/ 2 )
=115.401/783.7105
=14.72 %

Haemonetics's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=124.964/( (893.66+943.319)/ 2 )
=124.964/918.4895
=13.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Haemonetics  (NYSE:HAE) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=124.964/918.4895
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(124.964 / 1345)*(1345 / 2105.8515)*(2105.8515 / 918.4895)
=Net Margin %*Asset Turnover*Equity Multiplier
=9.29 %*0.6387*2.2927
=ROA %*Equity Multiplier
=5.93 %*2.2927
=13.61 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=124.964/918.4895
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (124.964 / 176.116) * (176.116 / 183.912) * (183.912 / 1345) * (1345 / 2105.8515) * (2105.8515 / 918.4895)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.7096 * 0.9576 * 13.67 % * 0.6387 * 2.2927
=13.61 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Haemonetics ROE % Related Terms

Thank you for viewing the detailed overview of Haemonetics's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Haemonetics (Haemonetics) Business Description

Traded in Other Exchanges
Address
125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Executives
Stewart W Strong officer: President, Global Hospital C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Anila Lingamneni officer: EVP, Chief Technology Officer HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Charles J Dockendorff director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Diane M Bryant director 2200 MISSION COLLEGE BLVD, SANTA CLARA CA 95054
Josep Llorens officer: EVP, Global Manufacturing HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Michelle L Basil officer: EVP and General Counsel HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Farris Maryanne Maunsell officer: VP, Chief Accounting Officer C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Roy Galvin officer: President, Global Plasma & BC C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Laurie A. Miller officer: SVP, Human Resources C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Mark W Kroll director PO BOX 23, CRYSTAL BAY MN 55323
Dan Goldstein officer: VP, Corporate Controller HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Christopher Simon, director, officer: President & CEO HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
James Darecca officer: EVP, Chief Financial Officer C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Burke William P. Mr. officer: EVP, Chief Financial Officer HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Lloyd Emerson Johnson director 16737 NEW PROVIDENCE LANE, CHARLOTTE NC 28277